Immuneering (IMRX) Stock Price Target 2026

The average analyst price target for Immuneering is $15.13, 302.4% above the current price. Of 10 analysts, 7 rate it Buy and 3 Hold. Targets range from $3 to $30. The latest change came on Aug 6, 2026, when HC Wainwright & Co. initiated coverage of Immuneering with a Buy rating and a $14 price target.

The Average Analyst Price Target for Immuneering is $15.13.

Price Target Range — 12 Quarters

Analyst Consensus — 10 Analysts

7Buy

3Hold

Consensus RatingBuy# Analysts10Avg. Consensus PT$15.13Upside to Avg. PT+302.4%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Immuneering Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 6, 2026	HC Wainwright & Co.	Andres Y. Maldonado	Initiate	Buy	$14
Jul 20, 2026	Needham	Ami Fadia	PT Raise	Buy	$11→$18
Jul 8, 2026	Cantor Fitzgerald	Li Watsek	Initiate	Overweight	—
May 19, 2026	Chardan Capital	Geulah Livshits	Maintained	Buy	$20
Mar 9, 2026	Needham	Ami Fadia	Maintained	Buy	$11
Nov 13, 2025	Chardan Capital	Geulah Livshits	Maintained	Buy	$20
Oct 31, 2025	Leerink Partners	Andrew Berens	Initiate	Outperform	$15
Sep 30, 2025	HC Wainwright & Co.	Ami Fadia	Maintained	Buy	$11
Sep 26, 2025	Chardan Capital	Geulah Livshits	PT Raise	Buy	$13→$20
Sep 25, 2025	Oppenheimer	Jay Olson	PT Raise	Outperform	$21→$30
Sep 15, 2025	Needham	Ami Fadia	PT Raise	Buy	$8→$11
Aug 26, 2025	Needham	Ami Fadia	Maintained	Buy	$8
Aug 14, 2025	Chardan Capital	Geulah Livshits	Maintained	Buy	$13
Jun 18, 2025	Mizuho	Graig Suvannavejh	PT Raise	Outperform	$8→$10
Jun 18, 2025	Needham	Ami Fadia	Maintained	Buy	$9
Jun 18, 2025	Chardan Capital	Geulah Livshits	Maintained	Buy	$13
Jun 5, 2025	Needham	Ami Fadia	Maintained	Buy	$9
May 7, 2025	Oppenheimer	Jay Olson	PT Cut	Outperform	$25→$21
May 6, 2025	Chardan Capital	Geulah Livshits	Maintained	Buy	$13
Apr 10, 2025	Needham	Ami Fadia	Maintained	Buy	$12